January 14, 2010
RXi, UMass To Study Age-Related Disease Treatments
By Matthew L. Brown
Worcester-based RXi Pharmaceuticals Corp. has inked a collaboration agreement with the University of Massachusetts Medical School to research how RXi's RNAi technology can be applied to age-related diseases.
The team will look into using RXi's self-delivering RNAi compounds to treat ocular diseases like macular degeneration, the leading cause of blindness in people more than 55 years old.
RXi has had encouraging results in previous work on the same subject. The collaboration with UMass will evaluate the delivery and activity of RNAi technology in preclinical models of ocular disease.
RNAi seeks to treat diseases by interfering with the genes thought to be responsible for those diseases.
WBJ Web Partners
Most Recent
Most Recent
0 Comments